{"name":"Veradermics, Inc.","slug":"veradermics-inc","ticker":"","exchange":"","domain":"","description":"Veradermics, Inc. is a biopharmaceutical company focused on developing innovative transdermal drug delivery systems for various therapeutic areas. The company has a robust pipeline with five drugs in clinical development, including VDMN-21 Patch and VDPHL01 in Phase 2 and Phase 3 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":62065000,"netIncome":-69995000,"cash":21766000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"VDMN-21 Patch Low Dose","genericName":"VDMN-21 Patch Low Dose","slug":"vdmn-21-patch-low-dose","indication":"Other","status":"phase_2"},{"name":"VDPHL01 BID","genericName":"VDPHL01 BID","slug":"vdphl01-bid","indication":"Insomnia","status":"phase_3"},{"name":"VDMN-21 Patch High Dose","genericName":"VDMN-21 Patch High Dose","slug":"vdmn-21-patch-high-dose","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VDPHL01","genericName":"VDPHL01","slug":"vdphl01","indication":"Relapsed or refractory multiple myeloma","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"VDPHL01 QD","genericName":"VDPHL01 QD","slug":"vdphl01-qd","indication":"Moderate to severe plaque psoriasis","status":"phase_3"}]}],"pipeline":[{"name":"VDMN-21 Patch Low Dose","genericName":"VDMN-21 Patch Low Dose","slug":"vdmn-21-patch-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"VDPHL01","genericName":"VDPHL01","slug":"vdphl01","phase":"phase_3","mechanism":"VDPHL01 is a small molecule that targets the H3 histone deacetylase (HDAC) enzyme.","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"VDPHL01 BID","genericName":"VDPHL01 BID","slug":"vdphl01-bid","phase":"phase_3","mechanism":"VDPHL01 BID is a small molecule that targets the H3 histamine receptor.","indications":["Insomnia"],"catalyst":""},{"name":"VDPHL01 QD","genericName":"VDPHL01 QD","slug":"vdphl01-qd","phase":"phase_3","mechanism":"VDPHL01 QD is a small molecule that targets the H3 histone deacetylase (HDAC) to modulate gene expression.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""},{"name":"VDMN-21 Patch High Dose","genericName":"VDMN-21 Patch High Dose","slug":"vdmn-21-patch-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxNeUpIQXNZVy04VUptaGd1dDRMa1YwWjRHQTdsUXg2R1RuV0xlX2g5M1diZFpXNmszX1pIMjJ6SERvcmpaN1RlRmtBSWtITVVMVERMcU55UHVsZzUxTDRoVVhsZ3lpQmJVM2psYzRWZ0ZzbTF1YzJKcUM2WDRXNlJtQTZOb1NXSDJkUW9kZl9iUXE0SDNMX2htMklDd2dGNmlCbkN1c2ZpOVp2VlNzZzItS1ZBSUstclUyQ1IxcHVKYTkwUDQxRl94eVRLZnlRVEN2RGtBbnkyalNINEJucV96Vy1XTXpDWk9IdGdPdWVOVkZadGVvY21hYlRGLTdJSklnNGpuSmNKX0ZwcTJuSmJtbmJhQUtrTmthQkVINmtoWFVUWEU1ZmJZU1IwTklKX3N4Tm5rVGtuN1NMQWFqbFQ1YXh2dVZmWENTemthWm1IZw?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight -","headline":"Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeut","sentiment":"positive"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPMERLS1NRQkdFSGVjbVVESUFjLW5aMW1abWt2RU5hWkhaSVV0d01mSmxUa3ZXTVF0dHNoVlVqSkh0SFNqbEZNWDMtWGFTeF9rb3hFVTFhem9ra0F0b0pTUzEwT1NMb1QwejVnSzV0NUhiMHRBYUgxbGN0Wm9WLVZSa1pjd3BrQzJuaFFzRzZucw?oc=5","date":"2026-03-11","type":"pipeline","source":"Yahoo Finance","summary":"Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal? - Yahoo Finance","headline":"Is Veradermics (MANE) Pricing Look Attractive After Recent Pharma Sector Reappraisal?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-11","type":"trial","source":"Indian Pharma Post","summary":"Veradermics completes enrollment in both Phase 3 male hair loss trials - Indian Pharma Post","headline":"Veradermics completes enrollment in both Phase 3 male hair loss trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOejdxLVlRdURidk9OZlo4Ui13WUJWeGpwY3pzLU9CVzBtS0xkT1QteFNONDVZUTVmY1VRNFplbGlieUJ1RDhBMG5Fa3ZscWR6c09aSTZvbXdudHY5bHUxMFFPNWZwUkN5X3JYMXlGUUtMNEZPRENSdE93VnpVbHp2Z1E3UzV0WW1aTW1WU3lPaGlWN2hJemV5VU9kTW5fXzRqYll5enJ2clZBdWs4dVE?oc=5","date":"2026-02-05","type":"pipeline","source":"Fierce Pharma","summary":"A cut above: Veradermics locks in $256M IPO and shares spike - Fierce Pharma","headline":"A cut above: Veradermics locks in $256M IPO and shares spike","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQaG5oV2JFYmlEVVRESHo4YnJVSklnZjRhT0wweUJtcUVIdmZhazBUQ1ZDeVFLdjlqejhmSVg4bnJrcmJrdV90RDhoUk9VVGRJeUZMbnIyc0NrN3VHY3lhSHJyLVpwMEFoQndJS3dwQ3FTRHA2RENrUWp1VVo2dklXQWwycVViQQ?oc=5","date":"2026-02-05","type":"pipeline","source":"pharmaphorum","summary":"Eikon, Veradermics close IPOs, as Salspera joins queue - pharmaphorum","headline":"Eikon, Veradermics close IPOs, as Salspera joins queue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPNi0tRzJhVWpWUW1CZ0JwZ05kVUlMcXZveGR6anlFVGh4Si1GdjQ0MWZBNUU2TTFGdjE1UGUyblhjSWwyUS0tWkdVekVGalFncHBVR2dKTGY2TlM4UExvLWRGWGh5VE9STW9IdURIMFFNVkpMMF81RjlvX0xrQlh2aXlzc0F2N0F5cTVqSk5hOHJSM2E2T2NWR0Q5RF9fYVUt?oc=5","date":"2026-02-04","type":"pipeline","source":"MedCity News","summary":"Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss - MedCity News","headline":"Baldness Biotech Veradermics Prices $256M IPO for Pivotal Tests of Pill for Hair Loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBtY1A1MG02MHp0blU3djVMMzhDazNzbmtJWnBOSmczcjVkbzllSDZvX2xLUzJHNS00M3hkbFVlN2dEQzhZREY5V3o3cWZVX1hBZlNj?oc=5","date":"2026-02-04","type":"pipeline","source":"FirstWord Pharma","summary":"Veradermics claims year's second IPO in upsized $256M offering - FirstWord Pharma","headline":"Veradermics claims year's second IPO in upsized $256M offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE54dTRxdld6T2ZteFI2MXZzZmhuUVBOVnJubWNXaWliTEE5WVk3S3QxZFV1UF9nM0R3bDdGN3BsR1NuN3hXMnpsX0lzSlU4R3pxVHc?oc=5","date":"2026-02-04","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Veradermics, Incorporated (MANE) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Veradermics, Incorporated (MANE) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE84bGFQX3M5Mmd6UjFDTjRpajhfWHB2SEZkSHUxTV9hSXhOZ3I5d2ZQOWJSNDk1M1lQMm9yc0djQXM3cWlsbmQ0a2xjRWI2dUdJWW00TldjNjZqUQ?oc=5","date":"2026-01-14","type":"pipeline","source":"TradingView","summary":"MANE Stock Price and Chart — NYSE:MANE - TradingView","headline":"MANE Stock Price and Chart — NYSE:MANE","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5QQjJRWS1zUzhYUS1Jd0JiQXZFdE45N1lNd09QajVYZUJLdmlpcHR5OVZRUzlsM1ZOMjN0REl3WE9LdjhMRTVhXzZBT3dQUi1nU2FR?oc=5","date":"2025-10-16","type":"pipeline","source":"FirstWord Pharma","summary":"Veradermics raises $150M to finish late-stage studies of oral hair loss treatment - FirstWord Pharma","headline":"Veradermics raises $150M to finish late-stage studies of oral hair loss treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQVkU3d080REVtLVJzRnREWDEtLWZEYTdMM01IaTM5ZS1rYUpkeTNaQ0xsV3pBTzNoaU8yRTRxZU9WUGExeDRVWGZBeWFMUU9BMC16TFNOck90UHRROXRSNlNFenNmZ0ZqbHhiczRXNWF2LVZhX0NmWFBhaWFKdS11SlZvcVR1N09kVm5QTVRaZ05QdGtvczdhRFZ3?oc=5","date":"2025-10-16","type":"pipeline","source":"BioSpace","summary":"Veradermics Gets $150M Series C To Advance Hair Regrowth Pill - BioSpace","headline":"Veradermics Gets $150M Series C To Advance Hair Regrowth Pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNVGJleEJjZ0JuLTNJR1dLQW1vajNrUl9JLVUyTGt1S3hyaV8xUDJCNldRVndXUExTZ2FkeGdMU0JoalVYRnNSZWJNVlp3TGVOYm5lMDVoYmdCTTBUYkdvWXJaMTE1cDF2enNXWXpDRzA1YlFkSkdKYVJWQW1aVjhmR0l5NWlYRHhpQl8wdFk2bmVEZV84d2FhWlZ3RTJKMlRTRGRCSzhB?oc=5","date":"2025-10-16","type":"pipeline","source":"Fierce Pharma","summary":"Veradermics, looking to tousle the pattern hair loss market, locks down $150M series C - Fierce Pharma","headline":"Veradermics, looking to tousle the pattern hair loss market, locks down $150M series C","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_2":2,"phase_3":3},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":62065000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-69995000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":21766000,"cashHistory":[],"totalAssets":152619000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}